65,437 trials
Cigarette Smoking · Schizophrenia · Bipolar Disorder
Primary: Number of Participants Who Are Abstinent at the Intervention Year 2 Assessment in Cohort 1 — 13; 32; 19 Participants — p=0.013
Epithelial Ovarian Cancer
Primary: Efficacy: Progression-free Survival (PFS) — 4.3; 2.8; 5.3; 2.8 Months — p=0.0220
COVID-19 Infection
Primary: Log10 SARS-CoV-2 Viral Load — 5.056; 5.110; -1.651; -1.881 Log 10 SARS-CoV-2 Viral Load Copies/mL
Alzheimer Disease · Cognitive Dysfunction · Mild Cognitive Impairment
Primary: Mean Change From Baseline to 24 Weeks in Vascular Dementia Assessment Scale Cognitive Subscale (vADAS-cog) Using the Average of Scores at 12, 18 and 24 Weeks. — -9.76…
Healthy · Cystic Fibrosis (CF) · Asthma
Primary: Ventilation Defects as Seen on Hyperpolarized Helium-3 MRI — 9; 13; 16 Participants
Heavy Menstrual Bleeding · Uterine Fibroid
Primary: Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA — 73.4…
Type2 Diabetes
Primary: Blood Pressure — 125.6; 126.0; 74.6; 75.1 mm Hg — p=0.56
Morbid Obesity · Surgery
Primary: Utility of ORi Providing Added Warning Time — 46.5; 87.0 seconds
Recurrent or Metastatic NPC
Primary: IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1 — 8.2; 21.4 months
Acne Vulgaris
Primary: Safety as Measured by Reported Adverse Events — 2; 4; 5; 5 TEAEs
Substance Use Disorders · Bipolar Disorder · Mood Disorders
Primary: Change in Timeline Followback of Substance Use (TLFB) — 2.3; 3.3 Days
Advanced Solid Neoplasm
Primary: Part A: Ratio of Maximum Observed Plasma Concentration (Cmax) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10) — 0.962 ratio
Hematopoietic Stem Cell Transplantation · Cognitive Impairments · Sleep
Primary: Cognitive Functioning (Neuropsychological Tests) — 0.24; 0.16; 0.43; 0.50 z-score
Complications of Corneal Transplant
Primary: Endothelial Cell Loss Post EK for Donor Corneas Preserved in Life 4°C and Optisol GS Corneal Storage Media — 20; 18 % endothelial cell loss — p=< 0.05
Malignant Glioma · Recurrent Glioblastoma
Primary: T-cell (Immunologic) Changes in Blood